QBIO Q BioMed (PNK) rises to $0.00010 on 21 Mar 2026: watch catalyst-driven momentum

We saw QBIO stock move sharply during market hours on 21 Mar 2026, trading at USD 0.00010 on the PNK exchange as volume ticked to 5,700 shares. The move follows small-cap biotech flows into speculative names in the Healthcare sector and a jump from a prior close of USD 0.00001, implying a intraday change near 9,900.00%. We flag the price action and note liquidity, market cap of USD 14,509, and the company pipeline as immediate context for traders and investors monitoring short-term momentum.

QBIO stock: intraday price action and volume

QBIO stock traded at USD 0.00010 on 21 Mar 2026 with 5,700 shares changing hands versus an average volume of 4,228, signaling above-average interest for this microcap. The market cap sits at USD 14,509 with 145,090,000 shares outstanding. We connect the price jump to low base effects and thin liquidity that can amplify percentage moves in PNK-listed biotech names.

QBIO stock: drivers and company update

Q BioMed Inc. (QBIO) is a Biomedical acceleration company in the Biotechnology industry. Product and pipeline items include Strontium Chloride SR89, Metastron, Man-01 for glaucoma, QBM-001 for pediatric non-verbal autism, and Uttroside-B for liver cancer. Company commentary, partnership activity, or micro-cap trading flows can trigger outsized moves. For company details see the Q BioMed site Q BioMed website and the company’s social updates on Twitter.

Valuation and financials for QBIO stock

QBIO stock shows extreme valuation metrics driven by a near-zero share price: Price to Sales 0.05, EPS -0.02, and book value per share -0.10317. Trailing metrics show operating cash flow per share 0.04338 and free cash flow per share 0.04338, but current ratio is 0.00889, indicating tight working capital. Enterprise value appears distorted by low price and reported enterprise value of 4,074,517 in raw data. Investors should weigh these metrics against the company’s small revenue per share and development-stage pipeline.

Technicals and Meyka AI grade for QBIO stock

Technical indicators show neutral momentum with RSI 52.05 and a strong ADX at 88.05, reflecting a strong short-term trend in a thin market. Meyka AI rates QBIO with a score out of 100: the score is 67.25, grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry metrics, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The grade is informational and not investment advice.

Risk factors and opportunities for QBIO stock

QBIO stock carries high volatility and liquidity risk given the tiny share price and low daily volume. Key risks include continued negative EPS, narrow cash buffers, and execution risks on clinical programs. Opportunities include pipeline progress, licensing deals, or any positive regulatory news that could re-rate the stock. Investors should expect large percentage swings and plan position sizing accordingly.

Price targets, scenarios and QBIO stock forecast

Meyka AI’s forecast model projects scenario targets to frame potential outcomes. A conservative 12-month base case is USD 0.00100 (implied upside 900.00% from USD 0.00010). A bullish scenario is USD 0.00500 (implied upside 4,900.00%). A downside scenario would be USD 0.00005 (implied downside -50.00%). Forecasts are model-based projections and not guarantees. Traders should treat these as scenario ranges tied to pipeline news and liquidity shifts.

Final Thoughts

QBIO stock rose to USD 0.00010 on 21 Mar 2026 during regular market hours on PNK, driven primarily by thin liquidity and renewed attention to small-cap biotech names. Our review highlights a mixed picture: attractive percentage upside in bullish scenarios but clear balance-sheet and liquidity constraints given EPS -0.02 and a current ratio of 0.00889. Meyka AI rates QBIO 67.25/100 (B, HOLD) based on benchmark and sector comparisons, financial metrics, and forecast inputs. For 12-month scenarios we model a base case USD 0.00100 (+900.00%) and a bull case USD 0.00500 (+4,900.00%), noting forecasts are projections and not guarantees. Investors should monitor upcoming earnings announcement on 2026-04-29, pipeline milestones, and daily volume before adding exposure. For more details and live signals consult our Meyka AI-powered market analysis platform and the company site Q BioMed website or the Meyka stock page for continuous updates QBIO on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.